Xiao X. Wei

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 189 citations · Full text

Urology, Oncology, Genitourinary Cancer +8

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 173 citations

Urology, Radiology, Radioligand Therapy +7

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Ziad Bakouny, David A. Braun, Sachet A. Shukla et al. · Nature Communications · 2021 · 154 citations · Full text

Tumor fraction in cell-free DNA as a biomarker in prostate cancer

Atish D. Choudhury, Lillian Werner, Edoardo Francini et al. · JCI Insight · 2018 · 142 citations · Full text

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features

Bradley A. McGregor, Rana R. McKay, David A. Braun et al. · Journal of Clinical Oncology · 2019 · 142 citations · Full text